In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

BMC Cancer

Research Article

Martin Pölcher¹  Kirsten Kübler¹  Marieke Mielich¹  Walther Kuhn¹  Christian Rudlowski¹  Michael Braun¹  Mathias Wolfgarten¹  Tobias Höller²  Reinhard Büttner³  Nicolaus Friedrichs⁴ 

[1] Department of Gynecology and Obstetrics, Center for Integrated Oncology, Bonn University Medical Center, Germany;Institute for Medical Biometry, Informatics, and Epidemiology, University of Bonn, Germany;Institute of Pathology, Center for Integrated Oncology, Bonn University Medical Center, Germany;Institute of Pathology, Center for Integrated Oncology, Bonn University Medical Center, Germany;Zentrale Klinische Forschung, University Freiburg, Germany;

关键词: Paclitaxel;    Antiangiogenic Therapy;    Antiangiogenic Effect;    Lymph Vessel Density;    Stage IIIC;   

DOI  :  10.1186/1471-2407-10-137

 received in 2009-09-18, accepted in 2010-04-13,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThe aim of our study was to analyze the effect of taxane-based chemotherapy on tumor angiogenesis in patients with advanced epithelial ovarian cancer.MethodsWithin a prospective phase II trial, 32 patients with stage IIIC and IV ovarian cancer were treated with either two or three cycles of neoadjuvant chemotherapy prior to cytoreductive surgery. Carboplatin (AUC5) and docetaxel (75 mg/m2) were administered intravenously in a 3-weekly schedule. Changes in intratumor microvessel density (MVD) were assessed with immunohistochemistry by staining pre- and posttreatment surgical tumor specimens with panendothelial, neovascular and lymphatic vessel markers.ResultsMean values of MVD defined by CD31, CD34, CD105 and D2-40 antibodies showed 12.3, 21.0, 2.7 and 3.1 vessels per high power field (HPF) before chemotherapy and increased after treatment to 15.3, 21.8, 4.8 and 3.6 per HPF, respectively. These changes were significant for CD31 (p = 0.04) and for CD105 (p = 0.02).ConclusionTaxane-based chemotherapy appears to promote tumor vascularization when administered every 3 weeks. A possible explanation is the secondary recovery of MVD in response to immediate cytotoxic and antiangiogenic effects of the chemotherapy. If confirmed prospectively, these findings favor shorter treatment intervals of taxane-based chemotherapy to counteract proangiogenic recovery.

【 授权许可】

CC BY   
© Pölcher et al; licensee BioMed Central Ltd. 2010